Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Steffen Bank, Aabenraa Sygehus
  • ,
  • Mette Julsgaard
  • Osama Karim Abed, Vejle Hospital
  • ,
  • Johan Burisch, Frederikssund Hosp, Med Dept
  • ,
  • Jacob Broder Brodersen, Esbjerg Sygehus, Odense Universitetshospital, Odense, Denmark.
  • ,
  • Natalia Konstantinovich Pedersen, Medical Department, Slagelse Hospital, Slagelse, Denmark.
  • ,
  • Anja Gouliaev, Danmark
  • Rullah Ajan, Herning Hospital
  • ,
  • Ditlev Nytoft Rasmussen, Hvidovre Hospital, Hvidovre
  • ,
  • Camilla Honore Grauslund, Hvidovre Hospital, Hvidovre
  • ,
  • Stine Roug, Hvidovre Hospital, Hvidovre
  • ,
  • Julie Galsgaard, Medical Department, Køge Hospital, Køge, Denmark.
  • ,
  • David Sprogøe Høyer Finsen, Svendborg Hospital
  • ,
  • Karoline Lindby, Medical Department, Bispebjerg Hospital, Bispebjerg, Denmark.
  • ,
  • Danish IBD Genetics Working Group
  • ,
  • Jeanette Sørensen, Aalborg University Hospital, Aalborg, Denmark.
  • ,
  • Lone Larsen
  • Malene Rohr Andersen, Gentofte University Hospital, Hellerup, Denmark.
  • ,
  • Ivan Brandslund, Vejle Sygehus, Vejle, Denmark.
  • ,
  • Mads Thomassen, Odense Universitetshospital, Odense, Denmark.
  • ,
  • Anders Green, Odense Universitetshospital, Odense, Denmark.
  • ,
  • Anders Bo Bojesen, Aabenraa Sygehus
  • ,
  • Signe Bek Sørensen, Aabenraa Sygehus, Odense Universitetshospital, Odense, Denmark.
  • ,
  • Ulla Vogel, Københavns Universitets Hospital
  • ,
  • Vibeke Andersen, Aabenraa Sygehus, Odense Universitetshospital, Odense, Denmark.

BACKGROUND: Anti-tumor necrosis factor-α (TNF-α) is used for the treatment of severe cases of IBD, including Crohn's disease (CD) and ulcerative colitis (UC). However, one-third of the patients do not respond to the treatment. We have previously investigated whether single nucleotide polymorphisms (SNPs) in genes involved in inflammation were associated with response to anti-TNF therapy among patients with CD or UC.

AIM: A new cohort of patients was established for replication of the previous findings and to identify new SNPs associated with anti-TNF response.

METHODS: Fifty-three SNPs assessed previously in cohort 1 (482 CD and 256 UC patients) were genotyped in cohort 2 (587 CD and 458 UC patients). The results were analysed using logistic regression (adjusted for age and gender).

RESULTS: Ten SNPs were associated with anti-TNF response either among patients with CD (TNFRSF1A(rs4149570) (OR: 1.92, 95% CI: 1.02-3.60, P = 0.04), IL18(rs187238) (OR: 1.35, 95% CI: 1.00-1.82, P = 0.05), and JAK2(rs12343867) (OR: 1.35, 95% CI: 1.02-1.78, P = 0.03)), UC (TLR2(rs11938228) (OR: 0.55, 95% CI: 0.33-0.92, P = 0.02), TLR4(rs5030728) (OR: 2.23, 95% CI: 1.24-4.01, P = 0.01) and (rs1554973) (OR: 0.49, 95% CI: 0.27-0.90, P = 0.02), NFKBIA(rs696) (OR: 1.45, 95% CI: 1.06-2.00, P = 0.02), and NLRP3(rs4612666) (OR: 0.63, 95% CI: 0.44-0.91, P = 0.01)) or in the combined cohort of patient with CD and UC (IBD) (TLR4(rs5030728) (OR: 1.46, 95% CI: 1.01-2.11, P = 0.04) and (rs1554973)(OR: 0.80, 95% CI: 0.65-0.98, P = 0.03), NFKBIA(rs696) (OR: 1.25, 95% CI: 1.01-1.54, P = 0.04), NLRP3(rs4612666) (OR: 0.73, 95% CI: 0.57-0.95, P = 0.02), IL1RN(rs4251961) (OR: 0.81, 95% CI: 0.66-1.00, P = 0.05), IL18(rs1946518) (OR: 1.24, 95% CI: 1.01-1.53, P = 0.04), and JAK2(rs12343867) (OR: 1.24, 95% CI: 1.01-1.53, P = 0.04)).

CONCLUSIONS: The results support that polymorphisms in genes involved in the regulation of the NFκB pathway (TLR2, TLR4, and NFKBIA), the TNF-α signalling pathway (TNFRSF1A), and other cytokine pathways (NLRP3, IL1RN, IL18, and JAK2) were associated with response to anti-TNF therapy. Our multi-SNP model predicted response rate of more than 82% (in 9% of the CD patients) and 75% (in 15% of the UC patients), compared to 71% and 64% in all CD and UC patients, respectively. More studies are warranted to predict response for use in the clinic.

OriginalsprogEngelsk
TidsskriftAlimentary Pharmacology and Therapeutics
Vol/bind49
Nummer7
Sider (fra-til)890-903
Antal sider14
ISSN0269-2813
DOI
StatusUdgivet - 2019

Bibliografisk note

© 2019 John Wiley & Sons Ltd.

Se relationer på Aarhus Universitet Citationsformater

ID: 145642745